|Place of Origin:||CHINA|
|Certification:||GMP , ISO 9001:2008|
|Minimum Order Quantity:||10g|
|Packaging Details:||Stealth And Discreet Packaging|
|Delivery Time:||Within 7 Working Days|
|Payment Terms:||Bank Transfer - Bitcoin - Western Union - MoneyGram|
|Supply Ability:||50 KG/Month|
|Product Name:||Cyproterone Acetate||CAS:||427-51-0|
|EINECS:||207-048-3||Appearance:||White Crystalline Solid|
pharmaceutical active ingredients,
pharmaceutical anabolic steroids
Product Name: Cyproterone Acetate
Melting point: 200-201°C
storage temp: 2-8°C
appearance: White Crystalline Solid
1. Used as an antiandrogen. Combinded with estrogen in the treatment of acne
2. The free alcohol is an anti-androgen; the acetate is both an anti-androgen and a progestogen. Combined with estrogen it is used in the treatment of acne.
3. antiparasitic, fasciolicide
|Product name||Cyproterone Acetate|
|CAS No.||427-51-0||Outer Packing||1KG|
|Production date||2018-06-19||Shelf life||2012-06-19|
|Items of analysis||Specification||Results|
|Characters||white or almost white crystalline powder||white crystalline powder|
|Solubility||practically insoluble in water, very soluble in methylene chloride, freely soluble in acetone, soluble in methanol, sparingly soluble in anhydrous ethanol.||Complies|
|Identification||First identification: A(IR). Second identification: B(TLC), C, D, E.||Complies|
|Specific optical rotation||+152°~+157 °||+155.6°|
|Melting point||About 210ºC||208.5~209.5ºC|
|Impurity F (RRT about 0.5)||≤0.4%||0.12%|
|Impurity E (RRT about 0.27)||≤0.2%||0.08%|
|Impurity B (RRT about 0.7)||≤0.15%||<0.05%|
|Impurity C(RRT about 1.5)||≤0.15%||<0.05%|
|Impurity G (RRT about 0.3)||≤0.15%||<0.05%|
|Loss on drying||Not more than 0.5%||0.21%|
|Sulphated ash||Not more than 0.1%||0.05%|
|Chloroform||Not more than 60ppm||45ppm|
|Ethyl acetate||Not more than 5000ppm||n.d|
|Methanol||Not more than 3000ppm||n.d|
|Dichloromethane||Not more than 600ppm||n.d|
|Acetone||Not more than 5000ppm||866ppm|
|Ethanol||Not more than 5000ppm||n.d|
1. Androgen-dependent conditions
CPA is used in the treatment of prostate cancer, precocious puberty, androgen-dependent skin and hair conditions such as acne, seborrhea, hirsutism (excessive hair growth), and androgenic alopecia (pattern hair loss), hyperandrogenism (e.g., in PCOS), and to reduce sex drive in sex offenders or men with paraphilias or hypersexuality. CPA is also widely used as a component of feminizing hormone therapy for transgender women. In the U.S., where CPA is not available, other drugs with antiandrogen properties like the diuretic spironolactone and the progestin medroxyprogesterone acetate are used instead to treat androgen-dependent conditions besides prostate cancer.
In the treatment of acne in women, a formulation of low-dose CPA in combination with EE has been found to result in overall improvement in 75 to 90% of patients, with responses approaching 100% improvement.
2. Birth control
3. Available forms
CPA is available in the form of oral tablets alone (high-dose; 10 mg, 50 mg, 100 mg) or in combination with ethinylestradiol or estradiol valerate (low-dose; 2 mg CPA) and in the form of ampoules for intramuscular injection (high-dose; 100 mg/mL, 300 mg/3 mL; brand name Androcur Depot). The high-dose formulations are used to treat prostate cancer and certain other androgen-related indications while the low-dose formulations which also have an estrogen are used as combined birth control pills and are used in menopausal hormone therapy for the treatment of menopausal symptoms.
5. Use during pregnancy is contraindicated.
Common side effects of CPA include hypogonadism and associated symptoms like demasculinization, sexual dysfunction, infertility, and osteoporosis, breast changes like gynecomastia, mental changes like depression, anxiety, fatigue, and suicidal ideation, vitamin B12 deficiency, glucocorticoid side effects like stretch marks, and elevated liver enzymes.
At very high dosages, CPA can cause cardiovascular side effects. Rarely, CPA can cause blood clots, liver damage, excessively high prolactin levels, prolactinomas, and meningiomas. Upon discontinuation at high dosages, CPA can have withdrawal effects, namely adrenal insufficiency.